& of course, for those who have the time, I highly recommend reading the full paper, here: doi.org/10.1016/j.ajcn…
But for those who prefer video or TW thread... HERE WE GO...
3/18) What the researchers did in this paper is perform a secondary analysis of pre-existing data from a 12-month RCT: the DIETFITS trial in which 609 adults aged 18-50 without diabetes were randomized to either a 12 m Low-carb diet (LCD) or low-fa diet (LFD).
4/18) Initial data showed LCD led to more weight loss than LFD at 3 and 6 mo, but that the between group diff in weight loss lost significance at 12 months
This was taken to be evidence against the CIM. However, as this paper reveals, there is more nuance to the story...
5/18) One important ? is why significance was lost at 12mo?
2 reasons...
i) Participant dropout. Each group lost ~80 participants, diminishing statistic power
AND
ii) Diet convergence: ‘Carb creep’ in the LCD group (132g/d) + carb drop in the LFD group (213g/d)
6/18) Even setting aside the dietary convergence, when missing data was imputed, the LCD group did in fact lose more weight at 12 m than the LFD group at all time points.
7/18) Moving on, Fig 2 shows a model of predictors of weight loss ➡️ larger circumferences represent better predictors of weight loss
🍽️🍽️Total fat & Calories were poorer predictors of weight loss
🍩🥭Carbs & GI and sugar are the superior predictors
Consistent with the CIM
8/18) In Table are 2 models examining the mediators of weight loss
When you add in Glycemic Load (GL) is added to the model in model 2, GL is highly significant (p=5.7x10-5) and calories (p=0.80) LOSE significance!
Let’s expand on this point...
9/18) Many think that LCD works bc it just makes you eat fewer calories, but that it’s actually the drop in calorie intake that’s driving the weight loss. This certainly is a contributing factor but...
10/18) These results show that GL is better than caloric intake at predicting weight loss, which may appear counterintuitive BUT can be made intuitive if you think about the components of Energy balance: Calories in & Calories out...
11/18) The CICO model, when taken in CLINICAL practice, usually focuses on CI because accurately measuring CO accurately is next to impossible (think, NEAT, TEF, body temp, etc.)
12/18) By contrast, if GL influences the hormonal milieu of the body, it dictates NOT ONLY hunger and caloric intake (CI) but also homeostatic mechanisms to maintain energy equilibrium, or tip it one way or another, through CO: NEAT, body temp, etc.
13/18) Simply put, one could actually make the argument that the CIM is actually a superior real-life ‘CICO’ model than the standard cal counting CICO model itself!
LOL If that doesn’t make sense, read ^ again and watch video for completeness
14/18) Other cool data presented in this paper consistent with the results already shared is that, in fig 5, a biomarker of low-carb/GL (TG/HDL) was strongly associated with weight loss whereas a biomarker of fat reduction (LDL+HDL) was not.
15/18) Finally, and beautifully, the authors put a bold prediction of the CIM to the test which is that those with higher basal insulin secretion would benefit most for GL reduction. Again, this is b/c in the CIM GL influences insulin to cause fat storage.
16/18) So, if someone naturally is an insulin hyper-secreter, the effect of the model is simply going to be amplified. As a result, those who secrete a lot of insulin probably benefit the most from reducing GL. Is that the case? As it turns out yes!
17/18) Clearly see an interaction b/w GL reduction and basal insulin
As you can see in the back left row, these persons who reduced GL most and were the insulin hyper secreters, lost the most weight!
18/18) In summary, this paper provides powerful evidence for two prediction of the CIM: (1) GL > Calories as a predictor of weight loss and (2) insulin hyper secreters benefit most from carb reduction.
Should Everyone Be Taking GLP-1s? (link at the end)
1/7) Over the past few years, we’ve witnessed a massive societal shift in opinion on GLP-1s: from supreme skepticism to the provocative question: “Should almost everyone be taking a GLP-1?”
Honestly, my own perspective leapfrogged from: “These are overhyped” to “Maybe they’re not being hyped enough”
Or more precisely: The benefits people ARE hyping may only be the tip of the iceberg.
These aren’t just weight-loss drugs.
Today’s 6,000-word deep-dive (link at the end) is intended to be your one-stop shop for understanding GLP-1s.
So, let’s start with a few fascinating facts you may not have heard.
2/7) Starting with brain health. Higher GLP-1 signaling appears associated with less amyloid in the human brain.
Now of course, correlation ≠ causation.
But is there actually any mechanistic reason to think GLP-1s could protect against Alzheimer’s disease in a weight-independent manner?
Yes.
3/7) GLP-1 signaling appears to inhibit an enzyme called BACE, which helps generate neurotoxic amyloid oligomers from amyloid precursor protein.
At the same time, GLP-1 in the brain improves insulin sensitivity, which leads to the inhibition of GSK3-beta, decreasing formation of tau tangles.
In other words: GLP-1 receptor agonists may directly influence BOTH major pathological hallmarks of Alzheimer’s disease: Amyloid & Tau… and do so independent of weight loss.
1/7) This is, without a doubt, the craziest “diabetes drug” ever invented.
It’s completed Phase II human clinical trials showing efficacy for reducing blood sugar and improving blood pressure. But the promise may extend far beyond that. In preclinical trials, it:
• Reduces fatty liver
• Increases energy expenditure
• Improves exercise endurance
• Cuts fat without sacrificing muscle
It’s called ATX-304. But how does it work?
2/7) The mechanism centers on one of the body’s master metabolic regulators: AMPK.
AMPK functions as a kind of cellular fuel gauge. When it’s “on,” it shifts the body away from energy storage and toward energy production—pulling fat out of fat cells and sugar out of the bloodstream and directing them toward muscles and energy output.
For that reason, AMPK has long been considered a highly desirable metabolic target.
There have been challenges (discussed in the full letter), but the key point is this:
ATX-304 appears to be a powerful AMPK activator. Now let’s look at some data.
3/7) In this study, researchers gave animals a high-fat, high-sugar diet to induce obesity.
One group (black triangles) was started on ATX-304. As you can see, ATX-304 almost completely prevented weight gain.
Then the researchers “flip-flopped” the groups at day 15—and later again. As you can see, treatment with ATX-304 either prevented weight gain or actively caused weight loss.
1/5) Mitochondria are often called the “powerhouse of the cell,” as if they’re just little batteries.
But they’re so much more. They’re living, fluctuating, even dancing signaling networks that determine how your body generates energy — and even how you age.
For example, one striking feature of supercentenarians, including the woman who lived to 117, is remarkably robust and youthful mitochondria.
The amazing thing about mitochondria is that unlike a battery or car engine, they can recover, heal, and renew themselves.
And you can help them do this: through how you live, how you eat, how you sleep, and potentially through cutting-edge mitochondrial peptides.
In today’s deep dive (link at the end), we discuss: How to Reboot Your Mitochondria.
2/5) Let’s start with something free:
Morning sunlight. This isn’t influencer wellness woo-woo.
Morning light helps kick off your “mitochondrial dance.”
Mitochondria constantly undergo cycles of fusion & fission
• Fusion helps mitochondria become more efficient and powerful.
• Fission helps isolate damaged mitochondrial components so they can be recycled through a process called mitophagy.
And research suggests light helps orchestrate these cycles.
3/5) Now let’s get more cutting-edge. Take the peptide SS-31.
Inside mitochondria is a highly folded inner membrane where energy production occurs.
A molecule called cardiolipin helps stabilize this membrane and organize the energy-producing machinery.
SS-31 is a mitochondrial-targeting peptide that binds cardiolipin and helps stabilize mitochondrial structure and energy production.
Researchers are now exploring it in aging, metabolic disease, heart disease, and neurodegeneration.
In a remarkable study published in Nature Metabolism, researchers put 12 healthy volunteers through a 7-day water-only fast and used advanced proteomics to track 2,923 circulating proteins simultaneously.
What they found was surprising—and suggests some people may stop fasting just before many of the benefits begin.
2/5) During the first two days, the body performed a fuel switch.
Proteins involved in fat transport and ketone production surged as participants transitioned away from glucose dependence. Basic. That’s fasting 101.
But the most interesting changes hadn't started yet… The real shift didn't begin until Day 3.
3/5) Day 3 marked a biological tipping point.
Researchers observed a massive wave of protein changes that dwarfed anything seen during the first two days.
Overall, 1,034 proteins changed significantly during the 7-day fast, with most of those changes emerging after the day 3 threshold.
This included proteins linked to cardiovascular health and proteins involved in the literal structure and function of the brain, offering new insights into how prolonged fasting may help prevent—or potentially even treat—certain neurological disorders.
Do Statins Cause Alzheimer’s: The Uncomfortable Nuanced Truth
1/5) Can statins cause Alzheimer’s disease and dementia? The honest answer is more complex than people give it credit for.
There are data suggesting statins can impair cognition. There are also data showing neutral effects, and even potentially protective effects. That contradiction requires resolution, not echo chambers.
Take a 2012 study in patients with pre-existing cognitive decline:
• Removing statins for 6 weeks improved cognition
• Re-challenging with statins for 6 weeks worsened cognition
Sounds alarming. But that’s not the whole story.
2/5) Many studies and meta-analyses find: no cognitive harm, neutral effects, or even potential protection against dementia
So, what’s going on? The answer likely lies in the interaction between:
• The pleiotropic effects of statins and
• Individual host physiology
Context matters. (Shocker)
Most Americans are metabolically unhealthy.
They have endothelial dysfunction and chronic inflammation.
On THAT metabolic background, statins may improve: endothelial function, blood flow, and inflammation Potentially benefiting both heart AND brain.
3/5) But there’s a flip side. As one example, common statins like atorvastatin may inhibit Complex IV activity in mitochondria.
And impaired Complex IV activity is associated with energetic dysfunction in the brain and Alzheimer’s disease.
So, there’s a push-pull. Some benefits. Some potential costs.